{
    "Clinical Trial ID": "NCT01246973",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Curcumin",
        "  4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week",
        "  Curcumin: 4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week",
        "INTERVENTION 2: ",
        "  Placebo",
        "  4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week",
        "  Placebo: 4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  a diagnosis of non-inflammatory breast adenocarcinoma (including in situ and bilateral)",
        "  scheduled to begin radiotherapy without concurrent chemotherapy; concurrent hormone or Herceptin\u00ae (trastuzumab)treatment is okay",
        "  can have been treated by lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment",
        "  can have had breast reconstruction",
        "  scheduled to receive 25-35 radiation treatment sessions (1 session per day) using standard irradiation fractionation (1.8-2.0 Gy per sessions) OR 16-20 radiation treatment sessions (1 session per day) using Canadian irradiation fractionation (2.2-3.0 Gy per session)(100, 101).",
        "  able to swallow medication.",
        "  three weeks must have elapsed after chemotherapy and surgery before the patient can begin the study",
        "  able to understand English",
        "Exclusion Criteria:",
        "  inflammatory breast cancer",
        "  previous radiation therapy to the breast or chest",
        "  concurrent chemotherapy treatment",
        "  concurrent treatment with anti-coagulants (e.g., coumadin\u00ae, warfarin\u00ae), or anti-EGFR (human epidermal growth factor receptor) drugs (e.g. Iressa\u00ae (gefitinib), Erbitux\u00ae (cetuximab, C225); aspirin is allowed",
        "  known radiosensitivity syndromes (e.g., Ataxia-telangiectasia)",
        "  collagen vascular disease, unhealed surgical sites, or breast infections"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Mean Radiation Dermatitis Severity Score",
        "  The outcome measures will be the severity of radiation dermatitis, using the Radiation Dermatitis Score (RDS), at the end of treatment in each treatment arm. (Objective: To examine the efficacy of curcumin in preventing and/or reducing the severity of dermatitis in radiation treatment site in breast cancer patients). The RDS score ranges from 0-4 with higher scores indicating worse outcome.",
        "  Time frame: 6 weeks",
        "Results 1: ",
        "  Arm/Group Title: Curcumin",
        "  Arm/Group Description: 4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week",
        "  Curcumin: 4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week",
        "  Overall Number of Participants Analyzed: 283",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: units on a scale  2.02         (0.05)",
        "Results 2: ",
        "  Arm/Group Title: Placebo",
        "  Arm/Group Description: 4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week",
        "  Placebo: 4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week",
        "  Overall Number of Participants Analyzed: 295",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: units on a scale  1.99         (0.06)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/344 (0.00%)",
        "Adverse Events 2:",
        "  Total: 0/342 (0.00%)"
    ]
}